SURVYR

AMGN

Amgen Inc.
$451.83
+$3.88 (0.87%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-7%+9%+26%+43%+59%Oct 2025Oct 2026Apr 202652w high $450.9852w low $288.00
AMGNSPY
Wall St. Highest PT $500.00 (+10.7%) Wall St. Avg PT $396.70 (-12.2%)
$283$341$399$457$515POC $337Hi $500Avg $397
Underwater Drawdown %Max DD -16.6%Current 0.0%
0.0%-16.6%
Relative Strength vs SPY+45.6% vs SPYOutperforming
+52%0%-52%
1W
+$26.89 (6.33%)
1M
+$33.70 (8.06%)
3M
+$66.44 (17.24%)
6M
+$118.29 (35.47%)
YTD
+$131.08 (40.87%)
1Y
+$167.62 (58.98%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
29 analysts · mean score 2.65
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$451.83
Average target$396.70
−$55.13 (−12.2%) downsideaverage target vs current price
CurrentAverageMedian
Low$225.00
Median$396.70
High$500.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-23 · Oppenheimer reiterated Outperform on AMGN
Reiterated
2026-10-21 · Barclays reiterated Equal-Weight on AMGN
Reiterated
2026-10-13 · Guggenheim reiterated Neutral on AMGN
Reiterated
2026-10-12 · BMO Capital reiterated Market Perform on AMGN
Reiterated
2026-10-12 · Wells Fargo reiterated Equal-Weight on AMGN
Reiterated
2026-10-09 · UBS reiterated Buy on AMGN
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$237.5B
P/E (last 12 months)27.3
P/E (next 12 months, estimated)17.9
52-week range$288.00 – $450.98
Revenue growth (latest quarter vs a year ago)+9.5%
Dividend yield2.29%
Analyst consensusHold (29)
Average analyst price target$396.70 (-12%)

What they do

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
74th percentile in sector
B+
12-1 return: +45.2%
Percentile within its GICS sector across the S&P 1500.
Growth
55th percentile in sector
C+
Revenue growth (YoY): +9.5%
Percentile within its GICS sector across the S&P 1500.
Value
50th percentile in sector
C+
Forward E/P: 5.7% · EBITDA/EV: 6.2%
Percentile within its GICS sector across the S&P 1500.
Profitability
90th percentile in sector
A
Profit margin: +23.0% · Return on equity: +91.5%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 51 of 499 · 12-month momentum 56.6%
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 29 of 589 · 12-month momentum 61.3%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

AMGN earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026After the close
EPS consensus$5.79 range $5.47–$6.09
Revenue consensus$10.1B 25 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026$6.29est $5.62+12.0%Above estimates
Apr 30, 2026$5.15est $4.77+8.0%Above estimates
Feb 3, 2026$5.29est $4.73+11.9%Above estimates
Nov 4, 2025$5.64est $5.01+12.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 11:14:19 ET
24-1025-0225-0525-0825-1126-0226-0426-080.006.29
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$10.1B+9.5%
2026-03-31$8.6B–
2025-12-31$9.9B–
2025-09-30$9.6B–
2025-06-30$9.2B–

Recent dividends

2026-08-21: $2.520 · 2026-05-15: $2.520 · 2026-02-13: $2.520 · 2025-11-21: $2.380 · 2025-08-22: $2.380 · 2025-05-16: $2.380 · 2025-02-14: $2.380 · 2024-11-18: $2.250

News & catalysts

More news
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
PR Newswire · 1h ago
State Street SPDR Dow Jones (DIA) Buys $15.9 Million More Goldman Sachs on Oct. 26
GuruFocus.com · 10h ago
AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND
PR Newswire · 23h ago
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Nasdaq · Oct 27
Dow Jones Biotech Giant Amgen Breaks Out Ahead Of Q3 Earnings Results
Investor's Business Daily · Oct 27
Rating changes
Reiterated
2026-10-23 · Oppenheimer reiterated Outperform on AMGN
Reiterated
2026-10-21 · Barclays reiterated Equal-Weight on AMGN
Reiterated
2026-10-13 · Guggenheim reiterated Neutral on AMGN
Reiterated
2026-10-12 · BMO Capital reiterated Market Perform on AMGN
Reiterated
2026-10-12 · Wells Fargo reiterated Equal-Weight on AMGN
Reiterated
2026-10-09 · UBS reiterated Buy on AMGN

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Khosla Rachna
SVP, Business Development · 2026-08-13
Sell
$521.4K
Khosla Rachna
SVP, Business Development · 2026-08-11
Sell
$825.1K
Grygiel Nancy A.
SVP & CCO · 2026-08-06
Sell
$402.2K
Grygiel Nancy A.
SVP & CCO · 2026-08-06
Sell
$792.3K
Miller Derek
SVP, Human Resources · 2026-08-06
Sell
$733.0K
Miller Derek
SVP, Human Resources · 2026-08-06
Sell
$832.9K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-24 11:14:19 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026